"Regorafenib is likely to join the list of useful therapeutics for metastatic colorectal cancer," he predicted. However, as patients having a performance status of 2 were not included, outcomes in this group are unknown, he cautioned. "I would encourage efforts to further improve its toxicity profile and would suggest candidate biomarkers, which have been reported by multiple groups, be followed up with appropriate diligence."
Dr. Grothey reported that he is a consultant to Bayer. Dr. Hurwitz reported that he is a consultant to Bristol-Myers Squibb and Genentech/Roche; receives honoraria from Roche; and receives research funding from a dozen companies.
Patrice Wendling contributed to this report.